Evercore ISI Raises Envista (NYSE:NVST) Price Target to $23.00

Envista (NYSE:NVST - Get Free Report) had its price target raised by research analysts at Evercore ISI from $19.00 to $23.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has an "outperform" rating on the stock. Evercore ISI's target price would suggest a potential upside of 13.92% from the stock's current price.

Several other analysts also recently issued reports on NVST. Piper Sandler cut their price target on Envista from $18.00 to $17.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. UBS Group cut their price target on Envista from $21.00 to $18.00 and set a "neutral" rating on the stock in a report on Monday, May 5th. Robert W. Baird raised Envista from a "neutral" rating to an "outperform" rating and raised their price target for the stock from $21.00 to $23.00 in a report on Tuesday, May 27th. Morgan Stanley set a $16.00 price target on Envista in a report on Tuesday, April 15th. Finally, Bank of America cut their price target on Envista from $26.00 to $23.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Envista presently has an average rating of "Hold" and an average price target of $20.23.

Envista Stock Performance

Shares of NVST traded down $0.53 during mid-day trading on Wednesday, hitting $20.19. The stock had a trading volume of 1,852,889 shares, compared to its average volume of 2,474,117. The company has a market cap of $3.42 billion, a PE ratio of -3.09, a PEG ratio of 1.28 and a beta of 1.00. The company's fifty day simple moving average is $18.65 and its two-hundred day simple moving average is $18.51. The company has a quick ratio of 1.82, a current ratio of 2.12 and a debt-to-equity ratio of 0.43. Envista has a fifty-two week low of $14.22 and a fifty-two week high of $23.00.

Envista (NYSE:NVST - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $0.24 EPS for the quarter, topping the consensus estimate of $0.20 by $0.04. The company had revenue of $616.90 million during the quarter, compared to analyst estimates of $608.17 million. Envista had a positive return on equity of 4.07% and a negative net margin of 44.90%. The business's revenue was down 1.1% on a year-over-year basis. During the same quarter last year, the firm earned $0.26 EPS. On average, equities analysts expect that Envista will post 1 earnings per share for the current year.

Institutional Trading of Envista

Hedge funds have recently added to or reduced their stakes in the business. US Bancorp DE increased its position in shares of Envista by 340.9% during the 4th quarter. US Bancorp DE now owns 21,919 shares of the company's stock valued at $423,000 after purchasing an additional 16,948 shares during the period. Charles Schwab Investment Management Inc. increased its position in shares of Envista by 8.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,317,631 shares of the company's stock valued at $44,707,000 after purchasing an additional 179,600 shares during the period. Keybank National Association OH acquired a new position in shares of Envista during the 4th quarter valued at $234,000. Assetmark Inc. increased its position in shares of Envista by 2.5% during the 4th quarter. Assetmark Inc. now owns 39,624 shares of the company's stock valued at $764,000 after purchasing an additional 983 shares during the period. Finally, M&T Bank Corp increased its position in shares of Envista by 4.2% during the 4th quarter. M&T Bank Corp now owns 16,621 shares of the company's stock valued at $320,000 after purchasing an additional 676 shares during the period.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.